Tepmetko Unia Europejska - polski - EMA (European Medicines Agency)

tepmetko

merck europe b.v. - tepotinib hydrochloride monohydrate - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Ceplene Unia Europejska - polski - EMA (European Medicines Agency)

ceplene

laboratoires delbert - histaminy дигидрохлорид - białaczka, szpikowe, ostre - Иммуностимуляторы, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). skuteczność preparatu ceplene nie została w pełni wykazana u pacjentów w wieku powyżej 60 lat.

Cuprior Unia Europejska - polski - EMA (European Medicines Agency)

cuprior

gmp-orphan sa - Триентин tetrahydrochloride - zwyrodnienie hepatotensywne - inne przewodu pokarmowego i przemianę materii narzędzia, - cuprior jest wskazany w leczeniu choroby wilsona u dorosłych, młodzieży i dzieci ≥ 5 lat z nietolerancją d-penicylamina terapii.

Inrebic Unia Europejska - polski - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - Środki przeciwnowotworowe - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Orladeyo Unia Europejska - polski - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - angioedemas, dziedziczny - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Tabrecta Unia Europejska - polski - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Vanflyta Unia Europejska - polski - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - białaczka, szpikowe - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.